Catalyst
Pharmaceutical Partners Inc.’s (Nasdaq: CPRX) rival Jacobus Pharmaceuticals presented
positive data for a drug that is similar to one being developed by
Catalyst sending the stock price tumbling 98 cents to close at $3.69.
Catalyst rival presents positive trial data
April 24, 2015 at 11:59 AM EDT
